Regulators finalized a rule Wednesday that would slash payments for drugs in the controversial 340B program and equalize some ...

AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears ...

The latest installment in BioPharma Dive’s visualization-focused series features a look at investors’ response to a trio of ...

J&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment ...

The occurrence of cancer in nine recipients — two of which involved evidence that a viral delivery tool integrated into ...

The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier ...

Historical data suggests the sector outperforms after midterm elections. And Democrats, newly in control of Congress, have ...

On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall ...

Wall Street analysts are already resetting projections for Rasonque — but company executives cautioned that it’s too early to ...

The San Diego biotechnology startup is one of several firms working on a cutting-edge technique with the potential to slow or ...

The startup is working on a medicine one of its investors claimed could have a broader reach than other approved drugs for a ...

The decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a ...